본문 바로가기

Evaluation of the Efficacy and Safety of DW1903 in Patients with Gastritis: A Randomized, Double-Blind, Noninferiority, Multicenter, Phase 3 study

문서 유형
연구출판물 · 학술지 논문
등재
KCISCIEScopus
저널 순위
JCR Q2Scopus Q1KCI Q2
저널
GUT AND LIVER18(1) · pp.70 · 2024
피인용
Web of Science 3Scopus 3KCI 2
FWCI (Scopus)
0.38
JCR IF
JCR 2023 3.4
ISSN
1976-2283

저자

  1. Kim, Jie-Hyun제1저자Yonsei Univ, Gangnam Severance Hosp, Dept Internal Med, Coll Med, Seoul, South Korea
  2. Jung, Hwoon-YongUniv Ulsan, Asan Med Ctr, Dept Gastroenterol, Coll Med, Seoul, South Korea
  3. Yoo, In KyungCha Bundang Med Ctr, Dept Internal Med, Div Gastroenterol, Seongnam, South Korea
  4. Park, Seon-YoungChonnam Natl Univ, Dept Internal Med, Med Sch, Gwangju, South Korea
  5. Kim, Jae GyuChung Ang Univ, Dept Internal Med, Div Gastroenterol, Coll Med, Seoul, South Korea
  6. Sung, Jae KyuChungnam Natl Univ, Dept Internal Med, Coll Med, Daejeon, South Korea
  7. Jang, Jin SeokDong A Univ, Dept Internal Med, Coll Med, Busan, South Korea
  8. Cheon, Gab JinUniv Ulsan, Gangneung Asan Hosp, Dept Internal Med, Coll Med, Kangnung, South Korea
  9. Kim, Kyoung OhGachon Univ, Gil Med Ctr, Dept Gastroenterol, Coll Med, Incheon, South Korea
  10. Kim, Tae OhInje Univ, Coll Med, Dept Internal Med, Haeundae Paik Hosp, Busan, South Korea
  11. Lee, Soo TeikJeonbuk Natl Univ, Jeonbuk Natl Univ Hosp, Dept Internal Med, Div Gastroenterol,Med Sch, Jeonju, South Korea
  12. Cho, Kwang BumKeimyung Univ, Dept Internal Med, Div Gastroenterol & Hepatol, Sch Med, Daegu, South Korea
  13. Chun, Hoon JaiKorea Univ, Dept Gastroenterol, Anam Hosp, Seoul, South Korea
  14. Park, Jong-JaeKorea Univ, Dept Gastroenterol, Guro Hosp, Seoul, South Korea
  15. Park, Moo InKosin Univ, Dept Internal Med, Div Gastroenterol, Coll Med, Busan, South Korea
  16. Jang, Jae-YoungKyung Hee Univ, Coll Med, Dept Internal Med, Div Gastroenterol & Hepatol, Seoul, South Korea
  17. Jeon, Seong WooKyungpook Natl Univ Hosp, Dept Internal Med, Daegu, South Korea
  18. Cho, Jin WoongPresbyterian Med Ctr, Dept Internal Med, Jeonju, South Korea
  19. 강대환Pusan Natl Univ, Dept Internal Med, Yangsan Hosp, Yangsan, South Korea
  20. 김광하Pusan Natl Univ, Pusan Natl Univ Hosp, Biomed Res Inst, Dept Internal Med,Coll Med, Busan, South Korea
  21. Kim, Jae J.Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Sch Med, Seoul, South Korea
  22. Kim, Sang GyunSeoul Natl Univ, Seoul Natl Univ Hosp, Liver Res Inst, Dept Internal Med,Coll Med, Seoul, South Korea
  23. Kim, NayoungSeoul Natl Univ, Dept Internal Med, Bundang Hosp, Seongnam, South Korea
  24. Lee, Yong ChanYonsei Univ, Severance Hosp, Dept Internal Med, Coll Med, Seoul, South Korea
  25. Hong, Su JinSoonchunhyang Univ, Dept Internal Med, Coll Med, Bucheon, South Korea
  26. Kim, Hyun-SooWonju Severance Christian Hosp, Dept Internal Med, Wonju, South Korea
  27. Lee, SoraDaewon Pharmaceut, Clin R&D Dept, Seoul, South Korea
  28. Lee, Sang Woo교신저자Korea Univ, Dept Gastroenterol, Ansan Hosp, Ansan, South Korea

초록

Background/Aims: H2 receptor antagonists (H2RA) have been used to treat gastritis by inhibit-ing gastric acid. Proton pump inhibitors (PPIs) are more potent acid suppressants than H2RA. However, the efficacy and safety of low-dose PPI for treating gastritis remain unclear. The aim was to investigate the efficacy and safety of low-dose PPI for treating gastritis.Methods: A double-blind, noninferiority, multicenter, phase 3 clinical trial randomly assigned 476 patients with endoscopic erosive gastritis to a group using esomeprazole 10 mg (DW1903) daily and a group using famotidine 20 mg (DW1903R1) daily for 2 weeks. The full-analysis set in-cluded 319 patients (DW1903, n=159; DW1903R1, n=160) and the per-protocol set included 298 patients (DW1903, n=147; DW1903R1, n=151). The primary endpoint (erosion improvement rate) and secondary endpoint (erosion and edema cure rates, improvement rates of hemorrhage, erythema, and symptoms) were assessed after the treatment. Adverse events were compared.Results: According to the full-analysis set, the erosion improvement rates in the DW1903 and DW1903R1 groups were 59.8% and 58.8%, respectively. According to the per-protocol analysis, the erosion improvement rates in the DW1903 and DW1903R1 groups were 61.9% and 59.6%, respectively. Secondary endpoints were not significantly different between two groups except that the hemorrhagic improvement rate was higher in DW1903 with statistical tendency. The number of adverse events were not statistically different.Conclusions: DW1903 of a low-dose PPI was not inferior to DW1903R1 of H2RA. Thus, low-dose PPI can be a novel option for treating gastritis (ClinicalTrials.gov Identifier: NCT05163756). (Gut Liver, Published online June 13, 2023)

키워드

GastritisPhase III clinical trialProton pump inhibitorsHistamine H2 antagonistsSYMPTOM RELIEFOMEPRAZOLEDA-9601DISEASE

식별자

Scopus EID
2-s2.0-85182501593
WoS UID
001013085200001
KCI
ART003044276